Regulation of Cellular Senescence by MiR-34a in Alcoholic Liver Injury
Overview
Authors
Affiliations
Alcoholic liver disease remains a major cause of liver-related morbidity and mortality, which ranges from alcoholic steatohepatitis to fibrosis/cirrhosis and hepatocellular carcinoma, and the related mechanisms are understood poorly. In this study, we aimed to investigate the role of miR-34a in alcohol-induced cellular senescence and liver fibrosis. We found that hepatic miR-34a expression was upregulated in ethanol-fed mice and heavy drinkers with steatohepatitis compared with respective controls. Mice treated with miR-34a Vivo-Morpholino developed less severe liver fibrosis than wild-type mice after 5 weeks of ethanol feeding. Further mechanism exploration showed that inhibition of miR-34a increased cellular senescence of hepatic stellate cells (HSCs) in ethanol-fed mice, although it decreased senescence in total liver and hepatocytes, which was verified by the changes of senescence-associated β-galactosidase and gene expression. Furthermore, enhanced cellular senescence was observed in liver tissues from steatohepatitis patients compared with healthy controls. In addition, the expression of transforming growth factor-β1, drosophila mothers against decapentaplegic protein 2 (Smad2), and Smad3 was decreased after inhibition of miR-34a in ethanol-fed mice. Our in vitro experiments showed that silencing of miR-34a partially blocked activation of HSCs by lipopolysaccharide and enhanced senescence of HSCs. Furthermore, inhibition of miR-34a decreased lipopolysaccharide-induced fibrotic gene expression in cultured hepatocytes. In conclusion, our data suggest that miR-34a functions as a profibrotic factor that promotes alcohol-induced liver fibrosis by reducing HSC senescence and increasing the senescence of hepatocytes.
Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers.
Liu Z, Ji F, Piao Y Front Genet. 2025; 15():1461404.
PMID: 39831201 PMC: 11739115. DOI: 10.3389/fgene.2024.1461404.
Hong X, Huang S, Jiang H, Ma Q, Qiu J, Luo Q Front Pharmacol. 2024; 15:1432480.
PMID: 39669199 PMC: 11635172. DOI: 10.3389/fphar.2024.1432480.
Gupta V, Sehrawat T, Pinzani M, Strazzabosco M Gastroenterology. 2024; .
PMID: 39251168 PMC: 11885590. DOI: 10.1053/j.gastro.2024.07.044.
Yang D, Jeong H, Kim M, Oh S, Lee K, Kim J Front Cell Dev Biol. 2024; 12:1393618.
PMID: 39139452 PMC: 11319911. DOI: 10.3389/fcell.2024.1393618.
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.
Karin M, Kim J Mol Oncol. 2024; 19(2):275-294.
PMID: 38874196 PMC: 11793012. DOI: 10.1002/1878-0261.13685.